NHS rolls out new multiple sclerosis jab that cuts hospital treatment time by 90%

Thousands of patients with multiple sclerosis are to benefit from a new 10-minute injection on the NHS that can help slow the progression of disability while cutting their treatment time in hospital by over 90%.

Around 9,000 patients in England currently receiving the drug ocrelizumab via an infusion can now be offered a jab that takes just ten minutes, following approval from the Medicines and Healthcare products Regulatory Agency, enabling them to spend less time in hospital receiving treatment.

The NHS will be one of the first healthcare systems in the world to offer the new injection to treat multiple sclerosis (MS), with stock of the drug set to be available in coming weeks.

Ocrelizumab (Ocrevus) is usually given via twice-yearly intravenous (IV) infusions, which can take up to four hours, but NHS patients in England will now be able to receive the drug via a quick ‘under-the-skin’ twice-yearly injection.

The drug, which is a disease modifying therapy for patients with active relapsing or primary progressive MS, has shown to be highly effective at halting the symptoms of MS by target a specific type of immune cell.

Clinical trials have shown the injection is just as effective as the IV treatment, with 97% of patients experiencing no relapses in their condition and no development of brain lesions over 48 weeks in trials.

As well as significantly reducing treatment time for patients, the injection could also save time for clinicians and help free up vital capacity in hospitals. It will also represent another treatment option for patients who have difficult-to-access veins.

Professor Sir Stephen Powis, NHS national medical director, said: “This new injection will drastically cut the time that regular treatment takes for those living with multiple sclerosis, meaning that thousands of patients can spend less time in hospital while helping free up clinicians’ time to see more patients as well as vital capacity on wards.

“Ocrelizumab has represented a huge advance in care in recent years as the first drug able to change the course of the disease, and we hope this innovative and speedier option will now make another significant difference in improving patients’ quality of life and help thousands avoid longer stints in hospital for treatment.”

Multiple sclerosis is a lifelong condition that is estimated to affect more than 150,000 people in the UK, including over 120,000 people in England. It is more common in women and each week around 135 people in the UK are diagnosed with MS.

It can affect the brain and spinal cord, causing a wide range of potential systems, including problems with vision, mobility, and balance, and can sometimes cause serious disability.

Nin Sambhi, 39 from Staffordshire, was diagnosed with relapsing MS in 2022. She currently takes ocrelizumab via infusion.

Nin said: “It’s great to hear that this new ocrelizumab injection has been approved. Ocrelizumab is working well for me right now and making me hopeful for a better and healthier future, but to be able to have an injection would be so much more convenient for me.

“At the moment, it takes around four or five hours to have my infusion and the logistics can be really difficult – I have two children under 10, so sorting out childcare can be challenging. This new treatment would mean significantly less time spent in hospital and more time with my family.”

There are three main types of MS – around 85% of those living with multiple sclerosis have relapsing remitting MS and experience episodic attacks of symptoms, and taking a disease modifying therapy can help reduce relapses and slow down MS.

Approximately 10-15% of patients have primary progressive multiple sclerosis, where symptoms gradually worsen and accumulate over several years, and there are no periods of remission.

Secondary progressive MS is a stage of MS which comes after relapsing remitting MS, but thanks to disease modifying therapies fewer people are likely to go on to secondary progressive MS, and for those who do, it can be delayed for longer.

Ceri Smith, Head of Policy at the MS Society, said: “We welcome the decision to license injections as a new method of delivering ocrelizumab (Ocrevus). Over 150,000 people live with MS in the UK, and many of them rely on disease modifying treatments like ocrelizumab to help reduce MS relapses.

“This method will expand the choices available to many MS patients and will mean more people can receive this treatment in a way that suits them.”

Ocrelizumab, manufactured by Roche, was first approved by the National Institute for Health and Care Excellence (NICE) for relapsing remitting multiple sclerosis in 2018, with further approval for primary progression multiple sclerosis in 2019.

Oliver Fairweather, UK Lead for Multiple Sclerosis, Roche Products Limited said: “We are pleased that eligible NHS patients across England will have access to the recently licensed ocrelizumab subcutaneous injection. This means that those eligible patients living with both relapsing and early primary progressive multiple sclerosis are gaining access to a subcutaneous formulation of an established disease modifying therapy. We couldn’t have achieved this milestone without the collaboration and support of the wider community.”

• Ocrelizumab is a disease modifying therapy for active relapsing MS or early primary progressive MS
• the MHRA decision applies to all countries across Great Britain
• an under-the-skin injection is an injection given in the fatty tissue just under the skin
• the new time-saving treatment is in line with NHS England’s focus on adopting less clinically demanding treatments, which drive productivity and improve patient outcomes
• in June, the European Commission approved the use of ocrelizumab as a twice-yearly injection for patients with MS in Europe.
• other treatments for relapsing MS include ofatumumab, which is also provided to patients via an injection which can be self-administered at home for patients with relapsing MS